Skip to content

Supernus Pharmaceuticals SUPN PT Freeport Indonesia (PTFI) mud rush incident insurance settlement receivable

PT Freeport Indonesia (PTFI) mud rush incident insurance settlement receivable at other companies

Freeport-McMoRan Inc. logo
Freeport-McMoRan Inc.FCX
$699M
Freeport-McMoRan Inc. logo
Freeport-McMoRan Inc.FCX
$0
Freeport-McMoRan Inc. logo
Freeport-McMoRan Inc.FCX
$0
Freeport-McMoRan Inc. logo
Freeport-McMoRan Inc.FCX
$0
Freeport-McMoRan Inc. logo
Freeport-McMoRan Inc.FCX
$0
CBL & Associates Properties logo
CBL & Associates PropertiesCBL
$244K

Other financials

Income statement

See full
Revenue$207.7M+38.6%
Gross profit$184.3M+37.5%
Operating income-$8.3M+18.8%
Net income-$2.3M+80.6%
EPS (diluted)-$0.04+81.0%

Balance sheet

See full
Cash & equivalents$186.3M+60.8%
Total debt$40.9M+26.6%
Total equity$1.1B+4.5%
Total assets$1.5B+11.4%

Cash flow

See full
Operating cash flow$66.5M+117%
CapEx--100%
Free cash flow$66.5M+120%

Valuation

See full
Market cap$2.58B+62.8%
Enterprise value$2.44B+62.3%
P/S3.3×+0.9×

Profitability

See full
Gross margin89.4%+1.0pp
Operating margin-7.8%-18.9pp
Net margin-3.7%-13.0pp
FCF margin27.9%+3.4pp

Returns & leverage

See full
Return on equity-2.8%-9.1pp
Debt / equity0.0×
Current ratio-0.5×

Where this comes from

Reported directly by Supernus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:InsuranceSettlementsReceivableCurrent.

The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Supernus Pharmaceuticals's pt freeport indonesia (ptfi) mud rush incident insurance settlement receivable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Supernus Pharmaceuticals's PT freeport indonesia (PTFI) mud rush incident insurance settlement receivable?
Supernus Pharmaceuticals (SUPN) reported PT freeport indonesia (PTFI) mud rush incident insurance settlement receivable of $1.9M in Q1 2026.